Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-05-28
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited and gene-based medicines across hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology and rare disease.
ai biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Scientific Proof Done, Franchise Proof Still Ahead
The first approved CRISPR therapy removed the existential science risk. The next five years are about proving that commercial throughput and at least one owned program can create a second durable revenue engine.

Analysis

Thesis
CRISPR Therapeutics has already cleared the basic science credibility hurdle with CASGEVY; the five-year equity upside now depends on turning that proof into at least one additional owned franchise with real commercial economics, most plausibly in autoimmune cell therapy or liver-directed cardiometabolic editing.
Last Economy Alignment
AI should help CRISPR Therapeutics design targets, run portfolio decisions and reuse platform know-how faster, while value capture stays anchored in regulated trust, IP, clinical data and manufacturing rather than software pricing. The limiter is that biology, approvals and treatment logistics still dominate scaling, and Vertex controls much of the CASGEVY downstream stack.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.7x (from 5 most recent analyses)
Reasoning
The rerating case does not require every program to work. It requires CASGEVY to become a durable economic stream, one owned franchise to earn credible late-stage or early commercial status, and management to keep enough downstream ownership that platform success reaches shareholders. That supports a multi-product biotech valuation rather than a single-asset optionality discount.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not software-like commoditization or an immediate cash crunch; it is proof conversion beyond CASGEVY. If H2 2026 and 2027 data fail to validate a second franchise, the market is likely to treat the company as a partner-dependent approved asset plus a cash-rich but uncertain pipeline. The biggest practical bottlenecks are regulatory proof, treatment throughput and how much downstream economics CRISPR can keep.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.44
They own gene-editing know-how, clinical data and a manufacturing base that get more valuable as AI makes discovery faster. The risk is that approvals, treatment logistics and Vertex's control of CASGEVY slow how much of that value shareholders actually keep.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$82.82
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case